On May 20th, the surging news reporter was informed that Shen Napeng, a member of the National Committee of the Chinese People’s Political Consultative Conference and Sequoia Capital Global, will submit five proposals including the reform of the R & D and approval system for innovative drugs and medical informatization. Topics such as intelligentization, construction of multiple prevention and treatment mechanisms for infectious diseases, and financial innovation and the development of science and technology in the Guangdong-Hong Kong-Macao Greater Bay Area.

As the only member of the National Committee of the Chinese People ’s Political Consultative Conference in China ’s venture capital industry, Shen Nanpeng understands the importance of scientific and technological innovation, digital upgrades and information applications for healthcare companies and institutions . He has three proposals this year focusing on this field, advocating and promoting the construction of a “pharmaceutical power”. Shen Nanpeng suggested in these proposals: Government departments need to continuously optimize the soil for pharmaceutical innovation, provide policy support for further strengthening the R & D and transformation of new drugs, and promote the construction of a “pharmaceutical power”; medical and health institutions need to pay attention to the application of big data and artificial intelligence in medical resources The investment should be “hard and hard”, make good use of digitalization and informatization, and improve the overall supply capacity of China’s medical services; the emergency response capacity of the Chinese department of infections needs to be raised to a strategic level to achieve the normalization of epidemic prevention capabilities, and the construction of distributed infectious disease report data sharing The internet.

Shen Nanpeng paid particular attention to the construction of the Guangdong-Hong Kong-Macao Greater Bay Area, and made suggestions for the development of technological innovation in the Greater Bay Area for three consecutive years. In two proposals this year, he separately proposed: First, to develop a cross-border digital stablecoin in Hong Kong, based on the construction of a digital technology-driven cross-border payment settlement network in China, Japan and South Korea, to build Hong Kong into an international in the digital economy era Financial center; second, help Hong Kong reshape its transformation by building a science and technology innovation hub, and achieve stable economic and social development.


“Optimize the recruitment rules, reasonably determine the medical insurance negotiation price, including reasonable planning for the decline in medicine”

The pharmaceutical industry is related to national economy and people ’s livelihood, and is a healthy China Important foundation. Under the guidance of the strategy of a powerful pharmaceutical country, new drugs are “available and affordable” as the basic goal of upgrading the drug security system.

Shen Nanpeng ’s proposal pointed out that in recent years, China ’s pharmaceutical industry has generally developed well, and the launch of new drugs, especially “life-saving drugs”, has accelerated significantly. In terms of accessibility, some problems need to be broken through: first, the effectiveness of new drug approval is still constrained by the number of personnel and insufficient experience, budget pressure is not conducive to the stability of the team and professional improvement; second, the lack of incentives and guidance of medical insurance for pharmaceutical innovation, the current medical insurance collection The adoption of a large-scale drug price reduction will benefit patients in the short term, but the long-term need to consider the enthusiasm of innovative pharmaceutical companies for research and development, and the mechanism of “doing a good job with good returns” still needs to be improved.
proposal believes that policy reforms to promote new drug R & D, clinical trials, and entry into the market will accelerate the entire process, stimulate the vitality of drug innovation, increase the availability of innovative drugs, and effectively solve the people ’s medical needs. An important direction for the quality of life of the masses. Therefore, the focus needs to be focused on the following two aspects:

First, provide input guarantee for the improvement of the professional ability of the review, introduce expert resources to support the training of drug review personnel, including Stable investment, expand the team of drug review centers, improve the overall professional capacity and effectiveness of drug review; implement the expert advisory committee mechanism, establish an expert review channel for overseas review experts, and strive to join the International Drug Certification Cooperation Organization (PIC / S) for new drug clinical trials , Innovative drug approval, priority review, etc. Establish normalized consultation channels, integrate domestic and foreign drug review expert resources, and strengthen the training of drug review personnel.

Second, optimize the recruitment rules, reasonably determine the medical insurance negotiation price, including rationally planning the drug decline. While accelerating the removal of “low-quality, ineffective” drugs and further promoting the price reduction of generic drugs, it is recommended to consider the actual production cost of drugs and reasonably determine the purchase price; for innovative drugs, it is recommended to fully consider the different life cycles of drugs and give certain price reductions Protect to protect the enthusiasm of innovation; explore the conversion of drug access from the “invitation system” to the “declaration system” to accelerate the entry of innovative drugs into medical insurance. It is recommended that after the new drug is listed, companies can apply for medical insurance without waiting for the time window for medical insurance negotiation, and realize “rolling applications for enterprises, rolling review of medical insurance, and updating the catalogue from time to time”, so that patients can use new drugs with significant clinical value as soon as possible.


Promote medical informationization and intelligent upgrade, and comprehensively improve medical soft power

Resolve the long-term imbalance of medical resources and build a shared construction for everyone China’s health needs us to focus on improving medical informatization and intelligence.

Shen Nanpeng ’s proposal believes that the level of medical informationization and intelligence in China needs to be accelerated. The specific manifestations are as follows: First, the investment of traditional medical resources is “hard and soft”, Informatization shortcomings severely restrict the improvement of the overall medical supply capacity; medical informatization has a poor foundation for the convenience of the people and benefits the people, “information islands” hinder the fair access of high-quality medical care; medical AI approval innovation is still insufficient compared to market development and international practice The regulatory environment for digital medical tools still needs to be optimized.

The proposal points out that China is currently developing strongly in the field of medical AI, which is a strategic opportunity to accelerate the upgrade of medical intelligence and seize the world ’s leading positionEncounter period. Therefore, the proposal suggests:


First, Promote the construction of a personal health file system at the national level , build a data foundation for the development of medical artificial intelligence and medical big data applications, including orderly promotion of the cross-border of electronic medical records database Geographical interconnection, gradually collecting medical and health information such as resident public health, inspection and testing, and referral for medical treatment, and building a national personal health record (PHR) system; referring to the foreign medical electronic data exchange bill, regulatory agencies can accelerate legislation on health information management and control Health / medical privacy management sets standards.

Second, deepen the reform of medical device review and accelerate the promotion of artificial intelligence medical device products, including exploring the establishment of special AI channels. Based on FDA experience, discuss the feasibility of establishing a special accelerated approval channel for AI medical devices, support more applications for registration of health / medical service products for C-end users; optimize the approval process, adapt to the rapid iteration characteristics of AI, The study proposes new standards for review, such as approving the use of historical data to evaluate the effectiveness of AI medical devices, overall shortening the data collection cycle of enterprises, and accelerating product launches.


Third, pilot some fee-charging projects and develop medical AI product liability insurance to promote clinical application and popularization, including promoting health insurance and price policies for medical AI, and exploring the introduction of medical AI Add a list of appropriate medical technology charges, promote the clinical assistant diagnosis and auxiliary decision support system of artificial intelligence in primary medical institutions by means of government purchase services; encourage commercial insurance to develop liability insurance covering the entire life cycle of medical AI products to share risks, refer to The experience of the first (set) major technical equipment insurance compensation mechanism has subsidized premiums for enterprises and stimulated the enthusiasm of medical institutions to use AI products and services.


Fourth, support the promotion of social forces to participate in the upgrading of medical information , introduce professional institutions to assist AI medical approval, including the absorption of high-level technology companies to support PHR data security, privacy protection, etc .; encourage professional third parties, Health technology assessment (HTA) agencies and others provide intellectual support in AI medical approval, and promote health economic evaluation of AI products and derived services.


Coordinating and improving the emergency response capacity of infection departments from a strategic perspective

Infectious Disease PreventionThe treatment and reporting process is undertaken in different hospitals in China, such as the Department of Infectious Diseases, Public Health and Medical Services. How to strengthen the system construction of the Department of Infectious Diseases to avoid the consequences of the unpredictable major epidemic caused by the epidemic has become an urgent issue.

Shen Nanpeng ’s proposal believes that there are currently four major bottlenecks in the national emergency system for infectious diseases and urgent breakthroughs are needed: First, under the concept of “prevention by medical care”, infectious subjects There is a lack of power guarantee for the property, the hardware investment is seriously inadequate, and the salaries of department doctors are significantly lower than their peers. Second, the hospital ’s preparation for prevention and control is insufficient, and the early warning and intervention techniques are weak, resulting in repeated challenges of doctor-patient infection and epidemic situations. Third, The medical and public health transition system is weak, emergency medical reserves are inadequate, and the prevention of infectious diseases lacks the thinking, system, and capacity reserves for the transition to peace and war. Fourth, there is information “intestinal obstruction” in the relevant departments of epidemic prevention and control, and the direct reporting system is subject to multiple The interference caused the failure of the early warning system of the epidemic.

Correspondingly, the proposal suggests:

First, the passive situation of “God of Wealth following the God of Plague” needs to be changed, Reposition the position of the Department of Infectious Diseases in the medical system at a strategic height to enhance the prevention and emergency capabilities as a whole;

Second, enhance the technical support capabilities of the hospital sense and enhance the hospital sense The evaluation weight of information and intelligent systems in the construction of hospital smart services, actively using scientific and technological means to improve the sense of hospital prevention, and publishing artificial intelligence, Internet of Things and other tools for non-contact clinical sign detection, medical protective equipment putting on and taking off, etc. Standardization;

Third, complete a special reserve system for public health emergency supplies, establish a rigorous and pragmatic contagion mechanism for the Department of Infectious Diseases, and scientifically plan production capacity reserves and do By the time the country normally reserves moderately, rapidly increases production capacity during wartime, and allocates reasonably;

Fourth, the law guarantees the efficiency of the direct network reporting system, and improves the joint prevention and control of zoonotic infectious diseases Legislation and accountability The use of Big Data technologies to build distributed data based on infectious diseases hospital and the CDC reports a shared network.


Accelerate the future transformation of Hong Kong with the construction of a science and technology hub

The “Outline of the Guangdong-Hong Kong-Macao Greater Bay Area Development Plan” puts “international technology with global influence” “Innovation Center” is one of the strategic positioning of the Greater Bay Area. A core proposition that can be tapped in this direction is to accelerate the future transformation of Hong Kong with the construction of a science and technology hub.

The proposal pointed out that ensuring the role of Hong Kong ’s science and technology hub is a demand in the international environment. Hong Kong has long served as a gateway connecting the mainland and the international market, and plays an important role in Sino-foreign scientific and technological exchanges; the Greater Bay Area needs a Hong Kong, which has different contributions to science and innovation, has significant advantages in higher education innovation and technology. There are more than 40 academicians of two academics, 16 national key laboratories, 6 universities in the world’s top 500, strong basic research capabilities and Shenzhen. The industrial advantages of the cities in the Bay Area can form a good complement, but the motivation for the transformation of scientific research results of Hong Kong universities in the Bay Area is not strong, resulting in a mismatch in Hong Kong’s insufficient contribution to innovation research and the high cost of investment in scientific research and development by mainland enterprises; 1. Resolving deep-seated contradictions requires Hong Kong to vigorously develop science and innovation.

On the specific operational level, the proposal believes that it is necessary to further open up Mainland scientific research topics to Hong Kong scientific researchers to promote central Facilitate the cross-border use of scientific research funds at all levels; promote mutual recognition of intellectual property rights between the two places, coordinate the identification standards for cross-border science and technology enterprises in the Greater Bay Area, and promote Hong Kong Bay Area research and large industrial interaction; leadership Bay Area Branch of the Task Force, co-ordination within the Bay Area and other major cross-border exchanges of researchers critical issues .